breast
cancer uk.
Prevention saves lives
IMPACT REPORT
ANDACCOUNTS
2023/24
Breast Cancer UK Ltd
Charity No. 11388661 Company No. 7348408

breast
cancer uk.
ABOUT BREAST CANCER UK
Our charitable objectives
Our guiding principles
Impact Report / A word from the Chair and CEO
OUR SCIENCE PROGRAMME
8-15
10-13
14-15
Breast Cancer UK'S Grant Funding Programme
Breast Cancer Prevention Conference
OUR EDUCATION PROGRAMME
16-19
Prevention hub and education content
Plans for our educational programme
17-18
19
OUR ADVOCACY PROGRAMME
20-23
Advocacy and campaigning
Collaboration
Next Steps
21
22
22-23
OUR GENEROUS SUPPORTERS
Regular Giving (The B Well Club)
Community and Events Fundraising
In Memory Gifts and Legacies
Corporate Partnerships
24-28
25
26-27
28
FINANCIAL REVIEW
29-32
30
30-31
31-32
32
Principal funding sources
Charitable Expenditure
Reserves policy
Results and closing position
STRUCTURE GOVERNANCE AND
MANAGEMENT
33-37
Structure
Governance
Staff
Risk Management
Statement of public benefit
Statement of Trustees Responsibilities for the Year
Ended 31 March 2024
Auditor's report
FINANCIAL STATEMENTS
34
34
35
35
36
37
38-40
41-53

ABOUT BREAST CANCER UK
Around 55,500 women and 370 men in the UK are diagnosed with breast cancer
every year and it is predicted that l in 7 women will get breast cancer at some
point in their lives. Yet, at least 30/0 of breast cancers are preventable.
That means that around 17,000 cases of breast cancer could be prevented each
year, saving countless lives, reducing suffering and reducing the cost to the N HS.
We believe there are many opportunities to reduce breast cancer rates in the UK
potentially saving millions of lives as a result. We give practical advice on how
people can reduce their risk of getting breast cancer by making simple changes in
their lives.
A unique aspect of our work focuses on the role played by hormone disrupting
chemicals in increasing the risk of breast cancer and we work with other
organisations to make our voice heard on this issue.
We also fund research that we believe could be a game-changer in the field of
breast cancer prevention.
Our mission is to prevent suffering caused by preventable breast cancers through
funding research, supporting individual behavioural change and campaigning for
effective public health and environmental protections.
We believe our work can have a significant impact on helping women and men
reduce their risk of developing breast cancer.
BREAST CANCER RATES
DOUBLED IN 50 YEARS
+24/0 SINCE 1996
AWOMAN'S LIFETIME
RISK OF BREAST
CANCER IS 1 IN 7
56,000 women diagnosed with breast
cancer every year
(for UK women born after 1960}
++++++i

96/.
of breast cancers appear in
women over 40
56,000
Women diagnosed
with breast cancer
each year in the UK
Breast
cancer is the
400
othmon
Men diagnosed
with breast cancer
each year in the UK
cancer in
the UK
30%
of breast cancer cases
can be prevented
Women will
develop breast
cancer at some
point in their lives.
17,000
Cases of breast cancer that could be
prevented each year

WE EDUCATE AND RAISE
AWARENESS OF THE
PREVENTABLE RISK FACTORS
FOR BREAST CANCERAND
PROVIDE PRACTICAL
INFORMATION TO HELP PEOPLE
REDUCE THEIR RISK
OUR
CHARITABLE
OBJECTIVES
WE CAMPAIGN FOR
POLICIES THAT
SUPPORT THE
PREVENTION OF
BREAST CANCER
WE SUPPORT SCIENTIFIC
RESEARCH THAT HELPS TO
UNDERSTAND AND
ADDRESS THE
PREVENTABLE RISK
FACTORS FOR BREAST
CANCER
OUR GUIDING PRINCIPLES:
Breast Cancer UK believes prevention is possible: more can be done to prevent
breast cancers by tackling lifestyle and environmental risk factors.
We are evidence based: scientific evidence is at the heart of our work with
sources clearly identified.
We champion high environmental and ethical standards: partnering with
companies and suppliers whose own ethical and environmental policies match
these standards.
We believe in the right to know.. we want to empower people by giving them
the information they need about the preventable risk factors for breast cancer,
so they can make informed choices.
We believe in collaboration: we will actively identify, seek and establish
collaborations with other stakeholders le.g. charities, think tanks, companies,
government and scientific institutions) to ensure we are effective in delivering
our goals.

WELCOME TO OUR
2023/24 IMPACT REPORT
A WORD FROM OUR CHAIRAND CEO
We are delighted to share our Impact Report and Accounts for the financial year
2023/24.
Our mission to make breast cancer prevention a reality is a great challenge that we
believe can be achieved through directly appealing to and nurturing our
supporters, collaborating with those who share our passion and determination and
investing in high-quality research 2nd education. This year we took strides towards
reaching this ambition by strengthening our visibility through an expansion of our
science-backed content and personalised advice, striving to match the needs of our
supporters.
We saw demand swell for our prevention education as we empowered greater
numbers of people to take prevention into their own hands with our prevention
quiz. We reached a significant milestone this year in hosting our first Breast Cancer
Prevention Conference, proudly partnering with Middlesex University. The
conference ignited new conversations and debates between scientists and experts
across the health and environmental prevention research sectors, exploring the
evidence, the gaps in our understanding and the priorities to act upon. We
strengthened our scientific grant programme with a steady investment in new
research grants and through new funding opportunities to cultivate greater interest
and diversify this important field of research.
This year's achievements enabled us to edge closer to our strategic targets, to
grow our scientific programme and investment, widen the impact of our education
through significantly expanding access to our personalised prevention planners,
empowering more people to make breast cancer prevention a part of their lives.
Our charity is entirely dependent on the generous donations of people, businesses,
groups, clubs, schools, trust & foundations and associations who believe in and
Want to support our work. Our achievements would not have happened without
their support. This year our growing number of supporters helped our charity
sustain financial growth for the third year running enabling greater investments in
our science and education. For this, we want to express our deepest gratitude and
appreciation. We wholeheartedly thank all of our valued supporters.
Our engaged Board of Trustees oversaw the governance of our team and
represented our charity with passion and commitment bringing a rich mix of skills
and experiences. We were delighted to welcome Beezy Marsh who is an author
2nd journ21ist, N2Zi2 Tingay who is a Senior Payments Project Manager, Lotte
Spencer who is a Marketing Director and Silvy Mardiguian who is Head of
Economics and Outcomes Research.

We were sad to say goodbye to Dr Britta Stordal, our Deputy Chair and Chair of
our Science and Public Affairs Committee. Britta's investment in the charity and
her skills, insights and passion have brought significant value to our cause. We
thank her for her commitment. We also said goodbye to Nichole Taske, who also
served on our Science and Public Affairs Committee bringing invaluable public
health policy knowledge to the charity. We thank Nichole for her commitment.
Finally, we farewelled Charlie Winstanley who also served on our Science and
Public Affairs Committee, bringing a breadth of policy and public health
knowledge. We thank him for his commitment.
Our passionate and talented team continued to expand to meet the swell in
demand for our work. With this growth comes a greater mix of skills, backgrounds
and experience enriching the work that we do. The team's tireless commitment to
achieving impact is hugely appreciated. Their feedback has told us that they love
working together to achieve one goal and that they feel their contribution is
making a difference. We thank all of our colleagues for their commitment and
dedication.
This year has shown that we can achieve our ambition and strive for more. As we
enter the last year of our strategic plan we remain steadfast in our commitment to
put breast cancer prevention at the core of the public health and environmental
responses to this devasting disease. We look forward to continuing to stride
forward with our supporters and partners to make preventing this disease a
priority.
Ruth Freeborough
Chair, Breast Cancer UK
Thalie Martini
CEO, Breast Cancer UK

OUR
SCIENCE
PROGRAMME

Our objectives were to;
Support high-quality, independent scientific research projects at universities or
research institutes within the UK.
Bring relevant, high-quality data and new research findings into the public
arena
Grow our scientific expertise and reputation in the field of breast cancer
prevention
A key mission of ours is to understand the preventable causes of breast cancer so
that we can translate this into practical measures that help reduce the impact of
breast cancer on people's lives. Our science programme is dedicated to exploring
the link between breast cancer and potentially harmful chemicals found in
everyday products and in our environment. We have made this our focus as we
believe that there is an urgent need to build greater evidence around the harms
these chemicals may be causing to our health and our breast cancer risk.
While there is convincing evidence to show that lifestyle factors such as alcohol
consumption and obesity can influence breast cancer risk, there is less wide-
ranging evidence available on the effects of environmental chemicals and possible
links with breast cancer.
Our grants programme aims to help fill the gap in our knowledge and
understanding of this complex area of breast cancer risk.

BREAST CANCER UK'S GRANT FUNDING PROGRAMME
RESEARCH PROJECTS
Completed projects
Brunel
University
London
Examining how Endocrine Disrupting Chemicals {EDCs) mixtures and a high-fat
diet affect breast cancer
Dr Elisabete Silva, Brunel University
The project examined the impact of mixtures of Endocrine Disrupting Chemicals
{EDC5) and saturated fats (that may result from a high fat diet) on early stages of
breast cancer. Findings from this project showed that 3D spheroids of normal
breast cells exposed to a mixture of Endocrine Disrupting Chemicals (EDCS) 2nd
saturated fats resulted in a more deformed structure compared to non-exposed
cells. This project also validated an exciting new three-dimensional breast cancer
model system known 25 "Breast-on-chip" This model contained three prominent
cell types found in the breast and more closely resembled how breast cells behave
in the body. The model will make future experiments involving mixtures of
Endocrine Disrupting Chemica15 IEDCs)/saturated fats more human-relevant.
UNIVERSITY
Current Projects
.fHULL
Investigating effects of per- and poly-fluoroalkyl (PFAS, or per- and
polyfluoroalkyl substances) substances on breast cancer development
February 2024 - Present
This PhD studentship project was awarded to Dr Mark Wade and PhD student Ms
Lucie Bilton of the University of Hull. This project aims to investigate whether
PFAS, or per- and polyfluoroalkyl substances ("forever chemicals") play a role in
breast cancer development and determine whether microplastlCS that can leach
PFAS, or per- and polyfluoroalkyl substances are found in breast tissue.
Normal breast cells will be exposed to PFAS, or per- and polyfluoroalkyl substances
at levels found in the blood and then be assessed for characteristics often found in
cancerous cells. The effect of long and short-term exposure will be an21ysed to see
what changes occur immediately and which develop over time. Breast tissue from
patients will also be analysed for microplastics.
10

College
LONDON
Measurement of Endocrine Disrupting Chemicals (EDCS) in breast cancer
November 2023- Present
This 18-month project was awarded to Dr Michael Antoniou with Research
Assistant, Charlotte O'Hern, at King's College London. This project aims to assess
the potential risks arising from Endocrine Disrupting Chemicals (EDCS) found in
everyday products that can potentially lead to or promote breast cancer.
Frozen breast cancer samples will be screened for oestrogen-like chemical
pollutants. Cancer and non-cancerous fatty tissue from the same breast will be
analysed. The results will be used to assess if there is a connection between the
amount and type of oestrogen-like chemical pollutants detected and breast cancer
growth and spread.
IWI UNIVERSITY OF
ABERDEEN
Evaluating the effects of BPA on breast cancer development
February 2023 - Present
This PhD studentship project was awarded to Prof Val Speirs and her PhD student
Ms Katharin2 Kusserow at the University of Aberdeen. This project is investigating
the effect of bisphenol A {BPA) on the non-cancerous breast and how it may
contribute to breast cancer development.
The project will involve a systematic review of existing literature to assess the
current understanding of how BPA affects breast tissue and computer-based
2ppr02ches to identify genes related to BPA exposure. Laboratory experiments will
then assess any potential involvement of those selected genes in breast cancer
development. BPA levels will also be measured in blood samples donated by breast
cancer patients.
College
LONDON
Biomonitoring 2nd molecular toxicity profiling of bisphenol mixtures
February 2022 - Present
This PhD studentship was awarded to Dr Michael Antoniou and his PhD student
Connor Powell at King's College London. This research project aims to complete a
biomonitoring study where urine samples are collected from the general public and
analysed for bisphenol compounds to help determine the levels of bisphenol
exposure in the UK population.
11

Publications
Di Pasquale A. Endocrine Disrupting Chemicals: the role they play in breast cancer.
Open Access Government. 2024.
https://www.openaccessgovernment.org/endocrine-disrupting-chemicals-the-
role-they-play-in-breast-cancer/1749631
Powell C, Mesnage R, Antoniou MN, Vandenberg LN. Low dose effects of
environmental chemicals: Bisphenol A as a case study. Encyclopedia of Toxicology,
Fourth Edition: Volume 1-9 2024.5.955-67 https://doi.org/lO.1016/B978-0-12-
824315-2.00762-4
A NEW STRUCTURE FOR OUR GRANT APPLICATION
ROUND 2023/24
Our most recent funding round called for applications that focus on the
relationship between Endocrine Disrupting Chemicals {EDCs) and breast cancer
risk" this was launched in November 2023 and closed in February 2024. For this
funding round, we developed a new funding structure. This year two separate
grants were available, known as our Foundation Award and Seed Award.
Our Foundation Award supports anchoring new principal investigators in the
research area of breast cancer prevention. Applications were asked to focus on
Endocrine Disrupting Chemicals {EDCs) (known or suspected) and breast cancer
risk. The Award will fund up to £150,000. primary applicants should be within 12
years of their PhD being awarded. Alongside the proposed funding for research,
Breast Cancer UK also offered an optional career coaching programme for the
duration of the grant to help support and develop the wider skills of the early
career scientist.
Our Seed Award is focused on chemicals and breast cancer risk. Funding can be
applied flexibly and may be utilised as a top-up for a project close to completion, to
nht2jn 2 cnprifir njprp nf pni ijnmpntr nr tn fi inA 2 njlnt nrniprt fnri i<pA nn
chemicals and breast cancer risk. The Seed Award is limited to a total cost of
£25,000.
Funding decisions will be finalised early summer 2024.
12

Independent Scientific Review panel
Breast Cancer UK'S Independent Scientific Review Panel provides vital expertise
and scrutiny to our growing grant programme and strengthens our communicable
science. The Panel, currently comprised of 14 expert members, are all independent
scientists or clinicians who have knowledge across the breadth of breast cancer
prevention. As well as providing peer review assessments in our grant programme,
the Panel is also consulted for our in-house authored science reviews, which is
critical for our Patient Information Forum Accreditation.
Health Information
Our health information continues to Strengthen through the publishing of several
major new documents (published onto our website and linked), including our Fibre,
the Gut Microbiome & Breast Cancer. Critical Windows of Susceptibility for Breast
and
HRT, Menopause and Breast Cancer scientific reviews.
As part of our continued development of accessible health education content, we
introduced health information on Life Stages, which incorporate Key Fact Sheets
based on the Unborn Baby and Breast Cancer Risk. Pregnancy and Breast Cancer
rn
r Ri
kand
Menopause and Breast Cancer Risk. These new resources follow the life course
and are intended to communicate how being at different stages of life can affect
our breast cancer risk as well as our susceptibility to Endocrine Disrupting
Chemicals.
In addition to our Life Stages resource, we overhauled the Chemicals pages of our
Reduce Your Risk section and introduced key fact sheets offering an accessible
summary to our latest scientific reviews. These new fact sheets include Parabens
2nd breast cancer, PFAS, or per- and polyfluoroalkyl substances 2nd breast Cancer
as well as a resource describing what the ￿￿L￿0&y&t0￿ is and how Endocrine
Disrupting Chemicals can affect our health.
We attended the London Maternity and Midwifery Festival in Febru2ry 2024,
which saw high engagement with our science content, both through our leaflet-
based information at our stand, and our oral presentation discussing foetal and
maternal exposures to Endocrine Disrupting Chemicals. Almost 350 health
professionals attended the Festival, with many taking resources from our stand to
their own clinical settings.
Association of Medical Research Charities Membership
In January 2024, we received notification that our application to join the
{AMBQ). was successful. The AMRC
supports medical research charities to enhance real-world impact through research
and innovation. The organisation ensures that member charities fund the highest
quality research through developing guides, training and carrying out regular audits.
We were delighted to be accepted as Introductory members to the organisation,
which reflects and bolsters our dedication to supporting excellent world-leading
research, and are now working towards Full membership.
13

Middlesex
University
London
BREAST CANCER
PREVENTION CONFERENCE
On the 21st-22nd June 2023, we held our inaugural Breast
Cancer Prevention Conference at Middlesex University. The
aim of the conference was to bring together scientists,
clinicians, students and members of other charities to
collectively acknowledge, debate and discuss the latest
developments in breast cancer prevention.
The conference combined two critical themes of breast
cancer prevention: the risks posed by environmental
chemicals and how lifestyle choices can affect breast cancer
risk.
Over two absorbing days, world-leading clinicians, scientists,
and researchers from as far afield as the US, Sweden and
Switzerland discussed and debated the latest research and
science around breast cancer risk factors.
The conference's climax was the panel discussion, consisting
of four leading scientists and clinicians. The. discussion saw a
robust debate on taking the science forward to ensure it
meets the criteria needed to drive regulatory and political
change.
Feedback from conference attendees was overwhelmingly
positive, with delegates praising all aspects of the conference
from the speaker line-ups and quality of the talks to the
venue and organisation. Furthermore, 100% of delegates who
filled in the feedback form said they were 'very likely, to
attend any future conferences held by Breast Cancer UK.
Public engagement on social media was also high across the
two days with many positive posts on the conference.
To read our 2023 conference report and view our conference
video, please click here.
14

PLANS FOR THE SCIENCE PROGRAMME
With the success of our last conference, we are aiming to host this as a biannual
event, with the next conference due in June 2025.
We intend for the focus of the event to be breast cancer primary prevention,
encompassing both lifestyle and environmental factors. We seek to continue to
provide a platform for scient15ts to come together, network, discuss and celebrate
the latest high-quality prevention research from across the globe.
Our grants programme continues to grow, and we anticipate opening a new grant
funding round in autumn 2024, with closing in early spring.
The focus of the funding will remain on Endocrine Disrupting Chemicals (EDCS)
and breast cancer risk and will mirror the structure of the previous 2023/2024
funding round.
Our science reviews continue to consolidate our understanding of breast cancer
risk factors and help to deliver educational information to the public through the
creation of daughter documents including key fact sheets, blogs and videos. We
plan to deliver science reviews focussed on several key and emerging risk areas
including phthalates" the microbiome and parabens.

OUR
EDUCATION
PROGRAMME

Our objectives were to:
Develop educational advice for members of the public who want to know more
about lifestyle and environmental risk factors for breast cancer
Improve access to practical solutions that help people take direct action to
reduce their risk
Reach and engage more young women with our message
Grow and consolidate our ambassador programme so that we help more
people understand how to reduce their risk.
PERSONALISED PREVENTION AND EDUCATION
Our personalised approach to supporting individual prevention gained ground this
year through the growth and continued improvement of our quiz and supporting
interactive digital resources. More people than ever took our quiz and many are
reporting back on their progress in maintaining the changes that they have put in
place to reduce their risk. Our plans for the future are to continue to scale this up
working closely with community and health partners to promote our practical
advice.
PREVENTION HUB AND EDUCATION CONTENT
There were over 71,000 users of the Prevention Hub this year, almost double that
of the prior year and over 3 times the Hub's 3-year target. Over 36,000 people
used the Chemicals iGuide' over 12,000 used the Everyday iGuide and over 15,000
used the Quiz.
About 1900 new people made a prevention plan and signed up to receive our
monthly Prevention Pulse magazine. This is over 4 times higher than the prior year,
thanks to additional promotion of the Quiz around Prevention Week, in June and
Breast Cancer Awareness Month, in October, plus the Quiz being made more
prominent on the webslte and being featured in all our outreach events and
education materials.
1900
12,000
Pulse sign up
15,000
Everyday
iGuide
Taken the
quiz
36,000 71,000
Chemical
iGuide
Hub users

A new version of the Quiz was also launched at the end of Breast Cancer
Awareness Month. The new version captures more details about Quiz takers, such
as their age, ethnicity and gender identity and this shows that the Quiz is attracting
a very good representation of the UK population, by age, region and ethnicity.
The new Quiz also offers people additional tailored email support for 6 months, if
they want to drink less alcohol, or get more active, to reduce their risk of breast
Cancer. Over 300 people chose extra support to drink less alcohol and about 350
people chose extra sUPPOrt to be more active.
People are also now being encouraged to retake the Quiz at least six months apart,
so that the impacts of adopting reduce your risk advice and activities can be better
assessed. Over 660 people retook the Quiz this year and over 200 of them did this
at least 6 months apart.
PREVENTION TALKS, INSIGHTS AND FEEDBACK
Demand for our education talks increased significantly this year. To 5UPPOrt this
demand and to enable wider access to our life changing prevention education, we
will develop a scalable outreach education programme to take our talks and
education to people across the country.
PREVENTION WEEK 2023
Age-related breast cancer risk:
During Prevention Week 2023, we focused on raising awareness of the significant
increase in breast cancer risk among women over 40. Representing over 95% of
new cases, this demographic highlights the importance of targeted prevention
efforts.
To address this significant issue, we developed a comprehensive campaign to
educate the public about the age-related factors contributing to breast cancer risk
and empowering individuals to adopt proactive measures for risk reduction. By
highlighting a different risk factor each day, we emphasised the creation of
sustainable healthy habits as a cornerstone of prevention.
We introduced a downloadable Weekly Wellness Planner to SUPPOrt people adopt
healthier lifestyles. This practical tool empowers users to track progress towards
their health goals, such as increasing physical activity, reducing alcohol
consumption, or improving nutrition.
BCAM 2023
Move More, Raise More, Reduce Risk:
Building upon the success of the previous year, our Breast Cancer Awareness
Month campaign in 2023 once again highlighted the powerful link between
physical activity and breast cancer prevention. Our signature 30-Day Challenge
encouraged participants to incorporate daily exercise into their routines, fostering
healthy habits while raising vital funds.
18

To further support our prevention community, we introduced the B Well Club, a
membership programme dedicated to prevention. Members received exclusive
wellnes5 advice, recipes, and exercise tips to empower them to make lasting
lifestyle changes.
By combining fundraising with education and support, we aimed to create a
comprehensive approach to reducing breast cancer risk.
PLANS FOR OUR EDUCATIONAL PROGRAMME
Next year we plan to make our prevention education even more accessible through
introducing a high quality education outreach programme to complement our
digital offer. The Quiz will be integrated into the outreach programme and will
continue to evolve with tailored email support for people who want to improve
lifestyle risk factors for breast cancer.
By nurturing relationships with the many people who take the quiz, and analysing
their responses, we will implement research measures to help us understand and
evaluate the benefits our quiz and tailored education have in reducing people's risk
over time. This will give us practical insights into the impact of our prevention
work.
Prevention
Saves
Lives
Start your prevention journey with ow qui
ulz and lannor.
Start¢)wz >
"Lovp thls.- Really iTrked the prev8ntlon plarL_ Very helpful
and important for me and ralsing my two tiny hurnar￿,
5kof
owt(y*ps
Chooso
preventio
C￿rinthe1utU1¢.
E¥￿ry￿e hassome riskofgetNngt*e3St
te*th￿aN
19

OUR
ADVOCACY
PROGRAMME

Our objectives for the last year were to:
Encourage a preventative approach by campaigning to improve legislation and
public he21th policy which helps to promote the primary prevention of breast
cancer.
Work at UK levels for policy and regulatory changes that help to protect
against breast cancer.
Raise the profile of our key messages amongst political decision makers by
establishing a network of activists to help us make our message heard.
OUR CAMPAIGNING
Our campaigning objectives remained consistent into our 23/24 year with a main
focus on.
Promoting preventative approaches to breast cancer and more broadly
prevention being put at the centre of healthcare policy.
Work to bring about policy changes at all levels of government that promote a
preventative approach in health policy. Principally, the scrapping of the
proposed Major Conditions Strategy and the return of a standalone Cancer
Strategy.
Advocate for a precautionary principle approach in chemicals regulation and
the publication of a Chemicals Strategy.
We put our case to top officials in the Department for Environment Food and
Rural Affairs. In collaboration with other organisations, we advocated to the
Government to keep high regulatory standards and not diverge from the European
Union's established regulatory system and EU REACH.
In preparation for the expected general election, we reached out to those in
opposition and identified key alignments in our policy priorities on cancer
prevention. We were proud to produce our first Manifesto for Breast Cancer
Prevention, merging our scientific knowledge with our policy expertise on breast
cancer prevention into a single document. Work on this began in the period
covered by this report.
ADVOCACY ANDCAMPAIGNING
This year we led on a number of consultation submissions including on the
Regulatory Management Options Analysis for bisphenols where we highlighted the
need for a greater focus on the cocktail effect on human health through exposure
to multiple chemicals in our daily lives. While we continued to point out to the
Government th2t the UK is falling well behind European countries such as
Germany who continue to pursue more stringent restrictions on the use and
distribution of bisphenols, it was frustratingly clear that the then Government was
not persuaded on the urgency to address either point.
21

Given the limited progress with the Government's regulatory and policy
developments on chemical exposures, thanks to the support of the Savitri Trustee,
we collaborated with our partners in the NGO working group on hazardous
chemica15 to develop a bespoke public awareness campaign on the impact of
harmful chemicals on our health including on our breast cancer risk. This work will
feed into Breast Cancer UK'S mobilisation campaign.
We continued to develop constructive relationships with the Department for
Environment Food and Rural Affairs (Defra) and the Department for Health and
Social Care (DHSC). We also engaged directly with Dr Philippa Whitford, then MP
and breast cancer surgeon and the then MP for Hitchin and Harpenden, Bim
Afolami who provided a message of support at our breast cancer prevention
conference and also supported our cause by sharing our quiz with his constituents.
Additionally, we wrote to.
Victoria Atkins MP (then Secretary of State for Health and Social Care)
Rishi Sunak MP (the Prime Minister)
Steve Barclay (then Secretary of State for Health and Social Care}
Rebecca Pow (then Parliamentary Under-secretary of State at the Department
for Environment, Food and Rural Affairs, with responsibility for chemicals
policy)
COLLABORATION
Our size as an organisation, the complexity of the policy areas that we work within
2nd the difficult politlC21 landscape that characterised this period made
collaboration an absolutely crucial part of our work. We continue to be a driving
force behind the NGO working group for hazardous chemicals which brings
together several organisations with interests in chemical regulation. A sub-group
was formed from this, the 'Health sub-committee,, which looks specifically at the
human health implications of exposure to harmful chemicals.
In addition, we have strong links with the EDC-Free Europe coalition and the
European Movement with whom we share information and ideas around alignment
with EU REACH (the European Regulatory System for Chemicals).
We have also continued to build alliances with organisations with whom we share
policy priorities including CH EMTrust, Animal Free Research, the Women's
Environmental Network, the Wildlife and Countryside Links and the Alcohol Health
Alliance.
NEXT STEPS
Our priority looking ahead is to launch our manifesto alongside the general
election, giving us a basis from which to influence policy development on breast
cancer prevention. We will target key MPS, Peers and policy-makers who we
believe should be engaging with our work.
22

We will continue to nurture our existing partnerships and recognise that these are
vital in making sure that we are around the table for key policy discussions.
However, we also recognise that there are other organisations, particularly health
charities, who may be campaigning for similar outcomes to ourselves, such as
improving the public's eating, drinking or buying habits and we will be actively
looking to partner with those organisations.
As we come towards the end of the existing Public Affairs Strategy, we will embark
on new planning work to set out a robust 3-year plan for our advocacy and
campaigning work in the years ahead. We will be looking to build a plan that
engages more closely with our supporters, empowering them to help drive the
change needed to make breast cancer prevention a policy priority.
ca
EST
EAST
CANCER
PREVENTION
23

OUR
GENEROUS
SUPPORTERS

This was a year of continued growth for our fundraising team. A year in which we
set the foundations for our long-term ambitions. An ambition to take our income
from just over £IM to over £4M within the next 5 years. Backed by an army of
committed supporters who are joining our mission to put prevention at the top of
the breast cancer debate. We thank them all for their invaluable support.
REGULAR GIVING (THE B WELL CLUB)
We developed and launched our new monthly regular giving offer - The B Well
Club. Each month we send our wonderful members fun and practical wellness
advice backed by science.
We have curated recipes, exercises, healthy habits and much more to help people
make small changes to their daily lives to improve their overall health and reduce
their breast cancer risk.
reas
cancer uk.
•J
Hello, <<First Name>>l
It's time to spring into life .1
Celthathys a￿ in tyder! We've rtwde it thr¢W￿ the LMg, dark i*)s of wirter,
aTrJ iv5 finally to Eet cth5th and eftioy tevry at ￿le V+ith nature.
If ￿'ve shbed away frcln riding y￿r th.ke or golng on Yfti&s tecause Gf
you're Tr)t alore. &Jt wth the 5WJ s40￿Y starting to retLYn, it's rErfect t7￿
to get back out tse aEain.
Sprfne ts a seawi of ¥tfvatSrn, w￿ther St's eatlng tetter, maklng for
exercF5e, ftmdraisir¢> or tyi"nE yow hand at that thing you've putting off
a ￿lIe, hit the activate buttcn!
P.S. FIcv*JEf5 arn't the thi￿ tl4t ￿ 5prv)g into life th15 seas(￿.
25

COMMUNITY AND EVENTS FUNDRAISING
People fundraising for us has long been the bedrock of our fundraising programme
and we're so grateful and thankful for their fantastic ongoing support.
This year 622 people ran event5 for us raising £480,504.84 an average of £772 per
fundraiser. Alongside this several supporters took part in organised events to
support our work this included:
Battle Cancer: We had 42 participants who raised £22,092.24
Kilt walk: We had 44 participants who raised £14,388.75
Skydiving: We had 24 participants who raised £33,990.49.
HERE'S SOME HIGHLIGHTS FROM OUR WONDERFUL FUNDRAISERS:
Thank you to Ivan Mond, a 90-year-old skydiver and his family who raised
£8,576. We ensured they had impactful media coverage during April 2023
here.
Thank you to Ashley and Oliver from Northamptonshire who trekked to
Everest Base Camp in August 2023, before attempting to climb and summit a
nearby peak - Imja Tse16,160m, 20,200 ft). They raised £5,916.63 h
Thank you to brothers Alex and Olly from Derbyshire who took part in the
Peak District Ultra Marathon at the start of October 2023 as their mum had
recently been diagnosed with breast cancer, they raised £7,187 here.
Thank you to James Roden and his colleagues from the RAF Lechlade who took
part in a pedalo challenge along the Thames in July 2023 and raised £14,041.26
here.
Thank you to Jessica Allan from the West Midlands and her sister Emma who
organised a 20-mile sponsored walk at the end of March 2023 to mark 20
years since their mum Helen Brayn passed away, they raised £5,088.75
including gift aid on JustGiving here.
We thank Karen Whitehead who, in June 2023, shaved her head in solidarity
with a friend who is currently going through breast cancer, raising £7,196 here.
Thank you to Nick White and his team TMAAT (Three Men and a Tent) who
raised £6,283 as they took part in a cycling challenge from London to Athens in
May and June 2023 h
We thank Peter Mackenzie from Cheshire who, in August 2023, took on his
second challenge for Breast Cancer UK. He played 250 holes of golf in 24
hours and raised £12,712.15 here.
Thank you to James Saunderson and 5 teams from The Unit Gym and Fitness
who took part in Battle Cancer Scotland in June 2023. James's wife Hazel was
being treated for Breast cancer. The group raised £15,052.78 here.
26

Thank you to Gavin O'Rourke from London who took part in the London
Marathon in April 2023, his wife has previously had breast cancer. He raised
£5,012.13 here.
Thank you to Hannah Blaber and friends from Knowle Tennis Club in Bristol
who held a 12-hour Tennis Marathon in May 2023 in memory of their friend
Malgo. They raised £5,500.471
Breast¥ '
27

PHILANTHROPIC GIVING
We are hugely grateful to those supporters who generously pledged their gifts
through Wills and donated in memory of a loved one. These gifts have enabled us
to make significant investments in our scientific research and our education
programmes both of which have grown thanks to the highly valuable support of
these donors.
Our two largest legacy gifts were from Mr Deryck Anthony Nott and from Mrs
Jean Mary Hastings.
We plan to continue to nurture and develop rewarding relationships with donors
whose dedication to our mission and our cause is key to strengthening and
growing our impact.
We wholeheartedly thank all of our valuable donors for choosing to support our
charity. We were extremely thankful to receive a number of other large in memory
gifts from Mary Edkins, Amanda Symes and Ailsa Thomas.
CORPORATE PARTNERSHIPS
We were supported by a wide range of wonderful businesses and their great teams
who do amazing things for us, from putting on golf days, throwing themselves out
of plane5, to donating a percentage of profits from the sale of products. We want
to thank all of the businesses and organisations who generously supported us this
year. Some highlights:
fljmhpr< A92jn<t f2nrpr r2j<prl FA 747 In tnt21 frnni nrtnhpr tn nprpmhpr.
We received £15,000 from Morelli Group Ltd who enjoyed a golf day
organised by the staff at Morelli Group in memory of one of the employee's
sisters - This was our biggest staff fundraising total from one event last year.
For the second year in a row, the staff at Olayan Group raised just under
£10,000 from their fundraising run for Breast Cancer UK.
Our plan for the future is to continue to build long-term business support from
companies and organisations that share our values and passion for our cause.
CAC
Al&Yth20J4
I/K
£674700
28

FINANCIAL
REVIEW

The Directors present their report with financial statements of the Company for
the year ended 31st March 2024. In preparing this report the Directors have taken
advantage of some of the special exemptions applicable to small companies.
PRINCIPAL FUNDING SOURCES
Total funds raised this year were £1,537,624 and saw income from donations
{excluding legacy gifts) growing by 33% on last year (£1,143,570 up from
£859,247). Total funds shows 2 generally sustained income generation compared
to last year's total funds raised of £1,585,839. This demonstrates the continuing
steady returns of our effort to grow the profile and outputs of our work. The team
continued to manage risk through routine risk assessments and regular budget
tracking and forecasting. Improving access to our messaging and education to
wider and more diverse audiences continues to be our priority. We approached the
development of our advice and awareness campaign through testing 2nd learning
from audience responses. We made a significant investment in relationship
management systems which has enabled us to take a more informed and targeted
approach to nurturing relationships with our supporters and audiences. The
balance of effective risk management and innovation continues to drive the growth
of our supporter community and the growth of our organisation.
Our largest source of income came from community fundraising £540,872 which
was made up of individual fundraising £424,442, and fundraising by educational
facilities, sports clubs and other clubs/societies £116,430. This was followed by
income from legacy giving of £321,407. The next highest sources of income were
from in memory giving £212,850, and individual giving £93,760.
We received £114,722 in fundraising from staff in corporate organisations. Finally,
we continue to partner with smaller companies and individuals too and would
particularly like to thank them for their ongoing support. Corporate donations
including cause-related amounted to £62,159.
CHARITABLE EXPENDITURE
We continued to manage spending cautiously due to rising concerns relating to the
cost-of-living crisis. We took steps to minimise costs and overheads while ensuring
we maximised funds spent on our charitable cause. As with last year, we
incorporated in our expenditure targets, strategic areas of investment to help
progress our growth and impact in line with the objectives of our strategic plan.
We closely reviewed investments quarter by quarter and assessed risk, as part of
investment decisions. This year, we spent 74/ (855,555) on charitable activities
and 26/. (304,456) on raising funds.
30

Our most significant investment was in our scientific research programme
{£397,909) followed by our education programme {£234,8041 as we continued to
increase activities to deliver accessible digital and print education content.
RESERVES POLICY
Purpose of the Reserves
The charity holds reserves to provide funding to support the continuation of the
charitable aims and objectives and the ability to meet financial commitments in the
event of a significant unforeseen reduction in income or increase in operational
costs.
Level of Reserves
The level of reserves is set by considering the uncertain nature of the charity's
income (which relies entirely on donations, legacies and grants) and the recurrent
expenditure and financial commitments the charity has. The charity has limited
overheads arising from accommodation as we do not have a central off ice space.
Hence our main financial commitments and running costs arise from staffing and
research grants.
Desigiiated Fund5
The charity is committed to funding research into the chemical and environmental
causes of breast cancer. Research grant applications from independent academic
institutions are considered periodically and approved at the Board level.
Designated funds represent funds approved by the Board for future spending on
research grants and other projects that aim to deliver our charitable objectives. The
level of designated funds is updated throughout the year to reflect the amount of
funds set aside for future projects until the funds are either committed to a project
or a decision is made to un-designate them if a project does not go ahead.
Free Reserves
Breast Cancer UK is committed to a programme of activity that meets our
charitable objectives. Given the uncertain nature of legacies, budgets are prepared
on the assumption that only in cases where we have already been formally
notified, are they included in income.
As a result, sudden large legacies or donations that are received during the
financial year can result in reserves being held that are more than Breast Cancer
UK'S reserves policy {free reserves) after allowing for designated funds.
To help us address this, our business plans now include a priority list of research
and education projects which align with our strategic priorities and the impact that
we want to achieve. Thus, excess legacies or unexpectedly large donations will be
directed promptly to these projects. We are continuing to monitor legacy income
for trends with 2 view to assessing the feasibility of including projections in future
income target setting.
31

ALltliorily.. MoiiiLoriiig arid Reportiiig
Ongoing monitoring of the reserves is undertaken during the year by the CEO,
Finance Director and Finance Trustee. We report the reserve position including
how funds are allocated to the Audit Risk and Resources Committee.
Reserve Policy Review
The Reserves Policy is reviewed annually by the Audit, Risk and Resources
Committee in February and approved by the Board of Trustees in March,
reviewing in detail the reserve position and taking into account prevailing
conditions in the charity sector and short-term and medium-term plans for the
charity.
At the Board meeting on 27th March 2024, the Trustees determined that
£313,940 should be held in emergency reserve. This represents 70°A of our most
vulnerable income stream and was calculated based on risk in the reduction of
income in those income streams. The total reserve level is sufficient to allow for
the financial implications of a downturn in income or the need to significantly
increase operational expenditure.
General unrestricted funds at year-end were £2,081,921 of which £712,782 were
designated funds, including £172,380 for science grants, £200,000 for the Science
Foundation Award, £36,000 for the Breast Cancer Prevention Conference and
£304,402 for other charity projects. Net of designated funds and our emergency
reserve of £313,940, excess free reserves were £1,055,199.
We were pleased to find that the negative impact on income from the cost-of-
living crisis and the war in Ukraine did not occur this year, with steady income
growth occurring throughout the year. Despite this, we recognise the continued
uncertainty and have therefore maintained a precautionary approach to ensure we
can weather the storm of any financial crisis ahead.
RESULTS AND CLOSING POSITION
The charity's income exceeded expenditure this year by £377,613 . This surplus
was welcome given the continuing investments we have made to grow our science
and education programmes this year. Our total income reduced by £33, 661 from
2023. Our total expenditure was 4% under budget. Total income exceeded our
annual budget target by £709,664 including legacy and grants. In light of the
ongoing cost of living crisis, we took a cautious approach to our target setting
whilst increasing our outputs and contents. This along with some generous
unexpected legacy gifts will explain the excess in income over targets.
Given our initial projection of £426,835 in planned deficit at 2023/24-ye2r end,
our very positive closing is a testament to our investment and risk management
policy, yielding extremely favourable returns and stability for our charity. We
enter the year ahead with confidence to Stay on track to grow sustainably and
achieve impact for our beneficiaries.
32

STRUCTURE
GOVERNANCE
AND
MANAGEMENT

STRUCTURE
Breast Cancer UK is a charitable company limited by guarantee (registration
number 073484081, registered on the 8th of November 2010 2nd registered as a
charity on the 15th of August 2001 (registered charity number 11388661. The
company was established under the Memorandum of Association, which
established the objects and powers of the charitable company. In the event of the
company being wound up, members are required to contribute an amount not
exceeding £10.
Our charitable objectives are as follows:
l.to advance health and save lives by encouraging a preventative approach to
breast cancer
2.to educate and raise awareness of the preventable risk factors for breast
cancer and provide practical information to help people reduce their risk. and
3.to support scientific research that helps us to understand and address the
preventable risk factors for breast cancer.
GOVERNANCE
The Directors of the Company, who are listed on the last page of this report are
also charity trustees for the purposes of charity law and under the Company's
articles are known as members of the Board of Trustees.
All members of the Board of Trustees give their time voluntsrily and receive no
benefits from the charity. Any expenses reclaimed from the charity are set out in
note 3 to the account5. Several trustees have suffered from breast cancer or are
close to people who have suffered from the disease. They use their own
experience in this area to assist the charity.
In recruiting Trustees, the members seek to ensure the charity benefits from a
broad range of different skills and expertise. Skills 2nd expertise represented on
the board include science and policy, medicine, cancer services, governance, law,
accountancy, fundraising, PR, business management and IT. In the event of skills or
individuals being lost due to retirements or resignations, the charity advertises for
specific skills and interviews are carried out to ensure the most appropriate
appointments are made.
This year we were sad to say goodbye to Britta Stordal, Nichole Taske and Charlie
Winstanley. Britta Stordal who served as Deputy Chair stood down at the end of
her second term on 23rd of September 2024. Nichole who had served as Trustee
since 11 December 2019, stood down on 19th September 2024 and Charlie who
served as Trustee since 30 June 2022 stood down on 5th June 2024. Both Nichole
and Charlie resigned due to increasing work commitments. We were delighted to
welcome four new Trustees to the board, Nazia Tingay, Lotte Spencer, Silvy
Mardiguian and Beezy Marsh who each who joined the board on Ilth March
2024.
34

Board of Trustees
Audit, Risk and
Resources
Committee
Science and
Public Affairs
Committee
STAFF
Breast Cancer UK'S staff are our greatest asset and we are committed to
supporting every employee to achieve their potential and achieve personal goals
which in turn will assist the organisation to achieve its objectives. Since 2020 and
in an effort to remain competitive, retain staff and attract talent, we have
continuously reviewed and evolved the team's functions, structure, benefits and
remuneration. This year we continued to expand our team across work areas to
reinforce resourcing and expertise. We conduct regular reviews of our salaries and
benefits package and we periodically consult with colleagues on work conditions,
ways of working and personal satisfaction to inform the continued evolution of our
unique organisational culture and values.
BREAST CANCER UK ORGANOGRAM
RISK MANAGEMENT
A risk register is established. Risk management sits with the CEO and ownership
sit5 Wlth Specific Committees and the Board. The Committees of the Board of
Trustees and the Board itself reviews the Risk Register at each meeting and it is
updated regularly. Mitigating actions are considered and reviewed regularly. All
policie5 and processes are under rolling review to ensure we are compliant with
regulation.
35

STATEMENT OF PUBLIC BENEFIT
The Trustees confirm that they have complied with the duty in Section 17 of the
Charities Act 2011 to have regard to the Charity Commission's General Guidance
on public benefit.
Our charitable objectives are enshrined in our Memorandum of Association and
Trustees to ensure that the charity's activities are carried out for the public benefit.
In July, these articles were formally amended with a special resolution passed to
amend our 'objects' clause through our three new strategic approaches:
to advance health and save lives by encouraging a preventative approach to
breast cancer
to educate and raise awareness of the preventable risk factors for breast
cancer and provide practical information to help people reduce their risk
to support scientific research that helps us to understand and address the
preventable risk factors for breast cancer.
This report allows us to show how our charitable funds are spent and the impact
that this has on those who access our information or use our services, as well as on
the wider challenge to reduce breast cancer incidence rates.
By Order of the Board
Ruth Freeborough (Chair and Director of the Board of Trustees)
Breast Cancer UK Limited
211212024
36

STATEMENT OF TRUSTEES RESPONSIBILITIES FOR THE YEAR
ENDED 31 MARCH 2024
The trustees (who are also the directors of Breast Cancer UK Limited for the
purposes of company law) are responsible for preparing the Report of the Trustees
and the financial statement5 in accordance with applicable law and United
Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting
Practice).
Company law requires the trustees to prepare financial statements for each
financial year which give a true and fair view of the state of affairs of the charitable
company and of the incoming resources and application of resources, including the
income and expenditure, of the charitable company for that period. In preparing
those financial statements, the trustees are required to
select suitable accounting policies and then apply them consistently
observe the methods and principles in the Charity SORP
make judgements and estimates that are reasonable and prudent
prepare the financial statements on the going concern basis unless it is
inappropriate to presume that the charitable company will continue in
business.
The trustees are responsible for keeping proper accounting records which disclose
with reasonable accuracy at any time the financial position of the charitable
company and to enable them to ensure that the financial statements comply with
the Companies Act 2006. They are also responsible for safeguarding the assets of
the charitable company and hence for taking reasonable steps for the prevention
and detection of fraud and other irregularities.
The trustees are responsible for the maintenance and integrity of the corporate
and financial information included on the charitable company's website. Legislation
in the United Kingdom governing the preparation and dissemination of financial
statements may differ from legislation in other jurisdictions.
37

## **INDEPENDENT AUDITOR ʼS REPORT TO THE MEMBERS OF BREAST CANCER UK LIMITED** 

## **Opinion** 

We have audited the financial statements of Breast Cancer UK Limited (the ‘Charity’) for the year ended 31 March 2024 which comprise the Statement of Financial Activities, the Balance Sheet, statement of cash flows and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). 

## **Opinion on financial statements** 

In our opinion the financial statements: 

- give a true and fair view of the state of the charitable company’s affairs as at 31 March 2024 and of its income and expenditure for the year then ended: 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the requirements of the Companies Act 2006. 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditorʼs responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRCʼs Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 

## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditorʼs report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. 

We have nothing to report in this regard. 

38 



**INDEPENDENT AUDITOR ʼS REPORT TO THE MEMBERS OF BREAST CANCER UK LIMITED Opinion on other matter prescribed by the Companies Act 2006** 

In our opinion, based on the work undertaken in the course of the audit: 

- the information given in the trustees’ report (incorporating the directors’ report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and 

- the trustees’ report (incorporating the directors’ report) has been prepared in accordance with applicable legal requirements. 

## **Matters on which we are required to report by exception** 

In the light of the knowledge and understanding of the Charity and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ Annual Report. 

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion: 

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or 

- the financial statements are not in agreement with the accounting records and returns; or 

- certain disclosures of trustees’ remuneration specified by law are not made; or 

- we have not received all the information and explanations we require for our audit. 

## **Responsibilities of the trustees** 

As explained more fully in the Trustees’ Responsibilities Statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the trustees are responsible for assessing the Charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the Charity or to cease operations, or have no realistic alternative but to do so. 

## **Our responsibilities for the audit of the financial statements** 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorʼs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud are set out below. 

39 



## **INDEPENDENT AUDITOR ʼS REPORT TO THE MEMBERS OF BREAST CANCER UK LIMITED** 

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following: 

- We enquired of management, which included obtaining and reviewing supporting documentation, concerning the charity's policies and procedures relating to: 

   - identifying, evaluating, and complying with laws and regulations and whether they were aware of any instances of non-compliance; 

   - Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected, or alleged fraud; 

   - The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations. 

- We inspected the minutes of meetings of those charged with governance. 

- We obtained an understanding of the legal and regulatory framework that the charity operates in, focusing on those laws and regulations that had a material effect on the financial statements or that had a fundamental effect on the operations of the charity from our professional and sector experience. 

- We reviewed the financial statement disclosures and tested these to supporting documentation to assess compliance with applicable laws and regulations. 

- We performed analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud. 

- In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments, assessed whether the judgements made in making accounting estimates are indicative of a potential bias and tested significant transactions that are unusual or those outside the normal course of business. 

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. 

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Councilʼs website at: [www.frc.org.uk/auditorsresponsibilities]. This description forms part of our auditor’s report. 

## **Use of our report** 

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006.  Our audit work has been undertaken so that we might state to the charity’s members those matters we are required to state to them in an auditor’s report and for no other purpose.  To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s members as a body, for our audit work, for this report, or for the opinions we have formed. 

12/12/2024 

………………………………. 

**Anthony Epton (Senior Statutory Auditor) for and on behalf of Goldwins Limited Statutory Auditor Chartered Accountants 75 Maygrove Road West Hampstead London  NW6 2EG** 

40 



FINANCIAL
STATEMENTS

Breast Cancer UK Limlted
Statement of financial activlties lincorporaiing an income and expenditure account)
For the ear ended 31 March 2024
2024
2023
Unrestricted Resiricted
Fund
Fund Total Fund
Unresiricted Restricted
Fund
Fund Total Fund
Note
Income from:
Donations and legacies
Charitable activities
Investments
1,443,8S9
21.118 1,464,977 1,433,844
83
14,471
137.441 1.S71,28S
83
14.471
72.647
72.647
Toial Income
1,516,506
21,118 1,537,624 1,448,398
137,441 1.585,839
Expendlture on..
Raising funds
Charitable acriviiles
Campaign costs
Education costs
Science costs
304,456
304.456
205,476
205,476
220.392
213,672
297,909
2.450
222,842
234,804
397,909
141,996
185,993
137,235
22,5SO
18,480
164,546
204,473
137,235
i 00,000
Total expentllture
1,036,429
123,582 1,160,01
670,700
41.030
711,730
Net income I (expenditure)
for the year
480.077 (102.4641
377.613
777,698
96.411
874,109
Tiansfers between funds
2,994
(2.9941
Net income I IcxpenditLtr¢)
before other recognised
gains and losses
480,077 1102,4641
377.613
780,692
93.417
874,109
Net movement in funds
480,077 1102,4641
377,613
780,692
93,417
874,109
Reconciliation of funds-
Total funds broughr fO￿ard
.601.844
151.389 1,753,233
821,152
5 7.972
879,124
Toial funds carried forward
2.081.921
48.925 2.130.846 1.601 ,844
ISl.389 1.753.233
All of the above results are derlved from conilnulng acrl¥lties. There were no oihei recognlsed galns or losses other than
those stated above. Movements in funds are disclosed In Note to the flnancial statemenis.
42

Breast Cancer UK Limited
Balance sheet
As at 31 March 2024
Com an no. 07348408
2024
2023
Note
Current assets:
Debtors
Cash at bank and in hand
191,082
2.251,559
38,746
,932,025
2.442,641
,970,771
Liabilities..
Creditors.. amounts falling due within one
year
12 (185,371)
1109,1101
Net current assets I Iliabilitiesl
2,257,270
1.861,661
Total assets less current liabilities
2,257,270
1,861,661
Creditors.. amounts falling due after one year 13
(126.424)
1108,428)
Total net assets I Iliabilitiesl
2,130,846
1,753,233
The funds of the charlty..
Restricted income funds
Unrestricted income funds..
Designated funds
General funds
48.925
151,389
712,782
,369,139
444,000
1,157,844
Total unrestricted funds
2,081,921
1,601,844
Total charity funds
2,130,846
1,753,233
The financial statements have been prepared in accordance with the special provisions for small
companies under Partl S of the Companles Act 2006.
Approved by the trustees on
02/12/24
and si9ned on their behalf by
ALTL
Ruth Freeborough
Trustee
43

Breast Cancer UK Limited
Statement of cash flows
For the
ear ended 31 March 2024
Note
2024
2023
Cash flows from operating actlvitles
Net cash provlded by I (used Inl operatlng
activities
246,887
769,964
Investing activities
Investment income received
72,647
14,471
Net cash generated from invesring activities
72,647
14,471
Net cash provlded by I (used Inl financing activities
Change in cash and cash equivalents in the year
319,534
784,435
Cash and cash equivalents at the beginning of the
year
,932.025
1.147,590
Cash and cash equivalents at the end of the year
2,251.559
1,932,025

Breast Cancer UK Limited
Notes to the financial statements
For ihe
ear ended 31 March 2024
Accounting policies
Charity information
Breast Cancer UK Limited is a private company limited by guarantee incorporated in England and Wales.
The registered office is The Union Building, 51-59 Rose Lane. No¥wich. Noifolk, NRI 18Y, England.
a) Basis of preparation
The financial statements have been prepared in accordance wilh Accounring and Reponing by
Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in
accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 102
effective l January 20191- (Charities SORP FRS 1021 and the Companie5 Act 2006.
The charirable company meets the definition of a public benefit entity under FRS 102. Assets and
liabilities are initially recognised at hi5toriial 1051 or transaction value unle55 Otherwise stated in the
relevant accounting policy or note.
bl Going concern
The trustees consider that there are no material uncertainties about the charitable company's ability to
continue as a 9oing concern. The trustees do not consider that there are any source5 of estimation
uncertainly at the reporting date that have a significant risk of causing a material adjustment 10 the
carrying amount5 of a55et5 and liabilitie5 Wlthin the next reporting peiiod.
cl Income
Income is recognised when rhe charity has eniitlement ro the funds, any performance condiiions
attached to the income have been met, it is probable that the income will be received and that the
amount can be measured reliablv.
Income from government and other 9rants, whether 'capttal' grant5 or 'revenue' grant5. 15 recogni5ed
when rhe charity has entitlement to rhe funds. any performance conditions atiached io ihe grants have
been met. it is probable thar the income will be received and the amount can be measured reliably and
is not deferred.
For legacies, entitlement is taken a5 the earlier of the date on which either.. the charity is aware that
probate has been granted, the esiate has been finalised and notification has been made by the
execuLvrls1 ILTr the chilflly Lhal a Lli51ributlDn will be made, ur when tjisiribuiion 15 ieceiveLt fium the
estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be
measured reliably and the charity has been notified of the execuior's intention to make a distribution.
Where legacies have been notified to the charity, or the charity is aware of rhe grantin9 of probate. and
the criteria for income recognition have not been met, then the legacy is a treated as a contingent
asset and disclosed if material.
Incomo r•coivod in advanc• of tho provision of a gpqcifiad g¥trvic• is d•f•rrqd until tho crit4ria for
income recognition are met.
dl Donations of gifts. seNices and facilities
Donated professional services and donated facilities are recognised as income when the charity has
conirol over the item or received rhe service. any conditions associated with the donaiion have been
met. the receipt of economic beneflr from the use by the charity of the item is probable and that
economic benefit can be measured reliably. In accordance with the Charities SORP IFRS 1021, volunteer
rime is noi recognised so iefer to the trustees, annual report for more information about their
On receipi. donated gifrs. professional services and donated facillties are recognised on the basis of
the value of ihe gifi to the charity which is the amount the charity would have been willing to pay to
obtain services or facilities of equivalent economic benefii on (he open market- a corresponding
amount 15 then recogni5ed in expenditure in the period of receipt.
e) Interest receivable
Inieresi on funds helij ot) deposii Is included when receivable and the amount can be measured reliably
by the charity,. this is normally upon notification of the interest paid or payable by the bank.
D Fund accounting
Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which
meets these criteria is charged to the fund.
Unrestricted funds are donations and other incoming resources received or generaied for the
charitable purposes.
Designared funds are unrestricred funds earmarked by the trustees for particular purpose5.
45

Breast Cancer UK Limited
Notes to the financial statements
For ihe
ear ended 31 March 2024
Accounting policies Icontinuedl
g) Expenditure and irrecoverable VAT
Expenditure is reco9nised once there is a legal or constructive obligation to make a payment to a third
party. it is probable that settlement will be Teqvired and the amount of the obligation can be measured
reliably. Expenditure is classified under the following activity headings..
Costs of raising funds relate to the costs incurred by the charitable company in inducing third
parties to make voluntary contributions to it, as well as the cost of any activities with a fundraising
purp05e
Fxp&nditiJrp nn rhArltAblp Artiviti•s incliJdp% the ro%ts of dglivgring services, IAnd•rtaken to fLJriher
the purposes of the charity and their a5socialed support Costs.
Oiher expenditure represents those irems not falling into any other heading
Irrecoverable VAT is charged as a cost against the activtty for which the expenditure was incurred.
h} Allocatlon of support costs
Resources expended are allocated to the pariicular activity where the cost relares direcrly to rhai
activity. However, the cost of overall direction admintstration of each activity, comprising the
salary and overhead costs of the central function. is apportioned on the basis which are an estimate,
based on staff c05t. of the amount attributable to each activtty.
Where information about the aim5. objectives and projects of the charity is provided to potential
beneficiaries, the costs associated with this publicity are allocated to charitable expenditure.
11 Operating leases
Rental charges are char9ed on a straight line basis over the term of rhe lease.
j) Tangible fixed asset5
Items of equipment are capitalised where the purchase price exceeds £ 1.000. Depreciation costs are
allocated to activities on tht basis of the use of the ielated assets in those activitles. Assets are
reviewed fur imP<iirtnEnl if iiicum5t¢ince5 indiLaie thEii carrying value Wn¢ay exceed theii net ie&iliSdble
value and value in use.
Depreciation is provided at rates calculated to write down the cost of each asset to Its estimated
residual value over its expected useful life.
kl Debtors
Trade and other debtors are recognised ar the settlement amount due after any trade discount offered.
Prepayments are valued ai the amount prepaid net of any trade discounis due.
11 Cash at bank and In hand
Cash at bank and cash in hand includes cash and short term highly liquid investmenls with a short
maiurity of Ehree months or less from the date of acquisition or opening of ihe deposii or similar
account. Cash balances exclude any funds held on behalf of service users.
ml Creditors and provision5
Creditors and provisions are recognised where the charity has a present obligation resuliing from a
past event that will probably result in the transfer of fund5 to a third party and the amount (Jue to
settle the obligation can be measured or estimated reliably. Creditors and provisions are normally
recognised at their settlement amount after allowing for any trade discounts due.
nl Financial instruments
The charity only has financial asset5 and financial liabilities of a kind that qualify as basic financial
insiruments. Basic financbal instruments are inirially recognised ar iransaciion value and subsequently
measured at iheir settlement value with the exception of bank loans which are subsequently measured
at amort15ed cost using the effective interest fflethod.
ol Pensions
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall
due.
46

Breast Cancer UK Limited
Notes to the financial statements
For ihe
ear ended 31 March 2024
2 Income from donation5 and legacies
2024
Total Unrestricted Restrlcted
2023
Toi31
Unrestricted Restiicred
DonatlOn5 and gift5
Legacies receivable
Grants
.122,452
321.407
21,118 1,143,570
321.407
776.806
657.038
82,441
859,247
657,038
55.000
55,000
.443,859
21,118 1,464.977 1,433,844 137,441 1,571,285
3 Income from charitable activities
2024
Total Unrestricted Restrlcted
2023
Toial
Unrestricted Restrlcred
Ticket sales
83
83
Total income from charitable
83
83
4 Income from investment5
2024
Total Unrestrlcted Restricted
2023
Toial
Unrestrlcted Restricted
Dep05ir account interest
72,647
72.647
14,471
14,471
72,647
72,647
14.471
14,471
47

Breast Cancer UK Llmited
Notes io rhe financial siatements
For the
ear ended 31 March 2024
5 Analysis of expenditure
C05t of
Charitable activities
ralslng Campaign Education
Stience
funds
costs
costs
cosis
Support
cosrs 2024 Toial
2023
Toial
Staff costs INote 7)
Consuliancy lees
Promoiional activittes
Subscripiions and memberships
Trainin9 COSt5
Cranrs
Recruitment costs
Prevention hub
Klck Start a Chemicals
Breast Cancer in Men
Donor enrry and plaiform fees
Staff welfare
Travel, accommod3tlon and meeilngs
Insurance
Website and IT
Printing, postage and stationery
Sundries
Ttlephone
Governance cost5
Bank Charges
Audii fees
Accountancy Fees
Legal and professional fees
Trustee5' meetings and training
1 $0,260 145,839 139,840 108,015 129.428
13,501
16,758
3,798
5.146
31.032
6,948
33,949
1.234
1.340
673,382
39,203
74,689
6,800
12.356
199,272
7,913
462,695
24,365
29.949
16.205
4.077
1.039
9.666
204
22.550
18.480
19.191
5.000
12.771
2.066
58.946
2.881
2,712
3,768
iio
2,760
3,384
20
1.041
8.689
2,242
65
199,272
3.103
1.560
2,003
321
926
1,330
1,330
34,968
6.135
24.991
534
53,658
2.412
2.647
3,240
34.968
6.135
16.997
534
53.658
608
2.647
3.240
932
3.008
3,103
951
1.804
49
49
7.200
7,200
2.592
2,592
4,580
4,580
2.060
2,060
157.014 171,683 349.153 245.530 1.160.011
61.410
58,884
45.483 1229,0491
4.418
4,237
3.273 116,4811
6.600
5.354
2.213
888
236.631
63.272
4.553
711.730
SLSPPOrt costs
Governance costs
Toral expendiiure 2024
304.456 222,842 234.804 397,909
1.160.011
The total expend5ture £1.036.429 was unrestricted 12023_ £670.700) and £123.582 12023.. £41.030) was restrlcted.
Analysis of expenditure Iprior yearl
Cost of
Charitable attivities
raisin9 Campaign Education
Science
funds
costs
costs
costs
Support
costs
2023
Total
Staff costs INote 7)
Consultancy lees
Promoiional actlvities
Subscriptions and rnembtrships
Trainin9 Costs
Grants
Recruitment costs
Preveniion hub
Kick Start a Chemicals
Breast Cancer in Men
Donor entry and platform fees
Staff welfare
Travel, accommodation and meeilngs
Insurance
Website and IT
Prlnting, postage and statlonerv
Sundries
Telephone
Finance costs
Governance costs
Audit fees
Accouniancy Fees
Legal and professional fees
Tru5tees' meeilngs and tfalnlllg
109.442
600
20.660
2.286
422
82.415 104,867
596
16.781
2.524
3,985
9,211
1,074
119
936
84.032
600
2.780
81.939
5.788
462,695
24.365
29,949
16,205
4,077
1,039
9,666
204
22,550
18.480
19,191
5.000
12,771
2,066
58,946
2.881
2.712
3.768
3.634
2.336
264
1.039
1.053
3.369
2.782
96
22.550
2.462
108
18,480
19.191
5.000
7.351
2.066
58.946
724
2.712
3.768
1.569
2,371
620
860
2.152
6.600
5.354
2.213
6,600
5.354
2,213
888
159.691
122.664 146,851
90.633 191.891
42.021
38.119
53,858
42.838 1176,8361
3.764
3.763
3,764
3.764 115,0551
205,476 164,546 204,473 137,235
711,730
Support £os¢s
Governance costs
Total expenditure 2023
711,730
48

Breast Cancer UK Limited
Notes to the financial 5taternent5
For the year ended 31 March 2024
Net incoming resources for the year
This is staEed after charging I crediting..
2024
2023
Auditors. remuneration (excluding VAT)..
Audit
6,000
5.500
Analysis of staff costs. trustee remuneration and expenses, and the cost of key management
personnel
Staff costs were as follows..
2024
2023
Salaries and wages
Social security cosrs
Employer's contribution ro defined pension schemes
Freelance staffs
579.127
44,300
20,010
29,945
419,754
29,517
13.424
673,382
462.695
The number of employees whose annual remuneration was more than £60,000 is as follows-
2024
2023
Numbor
Number
£70,001 £80,000
£8n.ooi-£on.ono
The total employee benefits including pension and national insurance contributions of the key
management personnel were £89,40912023.. £79,596).
The charity trustee5 were not paid or received any other benefits from employment with the charity in
the year12023.' £nill. No charity trustee received payment for professional or other services Supplied
to the charity IZ023.- £nil).
Trustee5' expenses include the payment or reimbursement of travel and subsistence costs totalling
£28012023.. £197) relating to attendance at meetings of the trustees.
Staff numbers
The average monthly number of employees during the year was..
2024
No.
2023
No.
Management and administration
Fundraising
Campaign5, science and Education
14
Related party transactions
There are no related party tian5actlQn5 to di5clo5e foi 2024 (ZO2 3". none).
There are no donations from related pariies which are outside the normal course of business and no
restricted donations from related parties.
49

Breast Cancer UK Limited
Notes to the financial 5taternent5
For the year ended 31 March 2024
l O Taxation
The charitable company Is exempi from corporatlon tax as all Its income Is charitable and is applied
for charitable purposes.
I l Debtors
2024
2023
Monies owed
Other debtors
Prepayments and accrued income
17,204
9,546
164,332
12,183
24.889
1 ,674
191,082
38.746
12 Creditors= amounts falling due within one year
2024
2023
Trade credltors
Taxation and social security
Grants payable
Other creditors
Accruals
20,401
12,975
139,514
3,345
9,136
15,414
83,769
9.927
185.371
109,110
13 Credltors: amounts falllng due after one year
2024
2023
Granis payable Inoie 141
126,424
108,428
126,424
108,428
14 Grants payable
Grants payable included in the financial statements as follows..
2024
2023
Grants payable is included within..
Current liabilities
Non-current1Sablliiies
139,514
126,424
83,769
108,428
265,938
192.197
Movements in the year-.
Balance at the beginning of the year
Released from previous periods
Amount accrued in the year
192,197
(125,532)
199,273
252.281
160.084)
265,938
192.197
15 Pension scheme
The charity operates a defined contribution pension scheme for all qualifying employees. The assets
of the scheme are held separately from those of the charity in an independently administered fund.
The charge to profir or1055 in respect of defined contribution scheme5 was £20,010 12023
£13,424).
50

Breast Cancer UK Limited
Notes to the financial 5taternent5
For the year ended 31 March 2024
16 Analysis of net assets between funds
General
unrestricted
Total
funds
Designated Restricred
Net current assets
Long term liabilities
1 ,495,563
{126.4241
712.782
48,925 2.257,270
(126,424)
Net assets at the end of the year
1,369.139
712.782
48.925 2.130,846
17 Movements in funds
Incoming
At the start resources &
of the year
gains
Outgoing
resource5 &
losses
At the end
Transfers of the year
Restrlcted funds:
Young people educational resource
Breast cancer in men resource
Bisphenols research project
Chemicals movement
General science research
47,570
1,567
19,802
2,450
80,000
47,570
1,355
11,3301
(19,8021
12,4501
(i 00,0001
20,000
Total restrlcted funds
151,389
(123,5821
48,925
Unrestricted funds=
Designated funds..
Science Grani Budget
Conversion of Online Quiz
HRT Scieniific brief
Breast Feeding resource
BCUK Prevenrion Conference 2025
Outreach Programme
Science Foundation Award
Seed Aw¢ird5
Reduce your Risk impact study
Developmeni of supper clubs
Developmeni of
Devolved parliaments outreach
Economic analysis tool
BCUK branding review
Mobilisation campaign
BCUK Podcast
BCUK Corporate film
Accessibility Audit
Website update5
420,000
io,000
9,000
5,000
(200,000) 147,6201
11 0,0001
19,000)
15,0001
172,380
36.000
37,000
200,000
50.000
50.000
23.400
24,317
5,000
5,000
20,000
15.000
20.36S
i 0.000
6,500
i 0.000
36,000
37,000
200.000
97,620
50,000
23,400
24,317
5,000
47.620
15,0001
{11,8001
8,200
15,000
17.365
io,000
6,500
io,000
13,0001
Total designated funds
444,000
512.582
(243,8001
712,782
General funds
1,157,844 7,003.924
(792,6291
1.369,139
Total unrestricted funds
1.601,844 1,516.506 11.036.429)
2.081,921
Total funds
1.7S3,233 1,537.624 11.160.011)
2.130.846
51

Breast Cancer UK Limited
Notes to the financial 5taternent5
For the year ended 31 March 2024
17. Movements in funds (Continued)
Purposes of restricted funds
Income, which is received for Specific purpose5, as
for example
grant5 and donations
atcounted for as restricted funds, with expenditure usually attributed over a specific period of time.
The charity manages restricted funds carefully. keep expenditure under regular review. and aim to
meet the specified purposes.
Purp05e5 Of designated fund5
Designated funds are the funds which have been set aside out of unrestricted funds by the trustees
for specific PLsfposes.
Movements In funds Iprlor yearl
Balance ar
Incoming
April resources &
Ourgoing
resources &
losses
Balance ai
31 March
2023
2022
gains
Transfers
RestrSc(ed funds:
Breast Density Research Project
Oxysterols Project
Creation and development of DLT
Young people educational resource
8rea5t cancer in men resource
Bisphenols research project
Chemicals movement
General Science research
2,994
12,9941
86
17,570
17,570
19,752
1861
30.000
2,391
50
25,000
80.000
47.570
1.567
19,802
2.450
80.000
(18,4801
86
(22,5501
Total restricted funds
57,972
137,441
141,0301
12,9941
151,389
Unrestrlcted funds..
Designated funds..
Science Grant Budget
CRM Developn7ent
Conversion of Online Quiz
HRT Scientific brief
8reast Feeding resource
200000
220000
420000
(25,0001
i 0000
9,000
5.000
i 0000
9.000
5,000
Total designated funds
225,000
244.000
125,0001
444,000
General funds
596,1 $2 1 ,204,398
(645,7001
2,994 1, I S7,844
Total unrestricted funds
821,152 1,448,398
1670,700)
2,994 1 ,601,844
Total funds
879.124 1,585.839
1711,730)
1.753.233
52

Breast Cancer UK Limited
Notes to the financial 5taternent5
For the year ended 31 March 2024
18 Reconciliation of net Income l (expendlture) to net cash flow from operarlng activitles
2024
2023
Net income I lexpenditurel for the reporting period
(as per the statement of financial attivities)
Dividends, interest and rent from investments
Ilncreaselldecrease in debtors
Increaselldecreasel in creditors
377,613
874,109
172,647)
(1 $2.3361
94,257
114,471}
113,364)
164,3001
Net cash provlded by I (used In) operatlng actlvities
246,887
781,974
19 Analy515 Of cash and cash equivalents
At31
March
2024
At l April
2023
Other
changes
Cash flows
Cash in hand
1.932.025
319.534
2.251,559
Total cash and cash equlvalents
1,932,025
319,534
2,251,559
20 Legal status nf thp charlty
The chariry is a company limited by guarantee and has no share capiial. The liabiliry of each member
in the event of winding up is limited to £ l.
53

breast
cancer uk.
info@breastcanceruk.org.uk
@£ www.breastcanceruk.org.uk
'@BreastCancer UK
o @breastcanceruk
,,facebook.com/breastcanceruk
linkedin.com/company/breast-cancer-uk
'￿[ Breast Cancer UK {2019}
BM Box 7767
London
WCIN 3XX
Tel: 0845 6801322
Preventlon saves Ilves
In